Home › Research › Topics › precivityad2-blood
precivityad2-blood
2 studies tagged precivityad2-blood, dated 2024-03-16 to 2024-08-10. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology 2024-08-10
- Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid 2024-03-16
Studies
2 studies carry this tag.
Date range
2024
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 1
- Diagnostics (Basel, Switzerland) 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Alzheimer's disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern.
-
The PrecivityAD2 blood test showed strong clinical validity, with excellent agreement with brain amyloidosis by PET.